Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
KRW 5320.0
(1.92%)
KRW 5320.0
(1.92%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 40.64 Billion KRW | -3.34% |
| 2022 | 42.05 Billion KRW | 25.38% |
| 2021 | 33.54 Billion KRW | -1.77% |
| 2020 | 34.14 Billion KRW | 3.24% |
| 2019 | 33.07 Billion KRW | -6.02% |
| 2018 | 35.19 Billion KRW | -2.52% |
| 2017 | 36.1 Billion KRW | -2.67% |
| 2016 | 37.09 Billion KRW | 1.69% |
| 2015 | 36.47 Billion KRW | 3.44% |
| 2014 | 35.26 Billion KRW | -9.5% |
| 2013 | 38.96 Billion KRW | -8.37% |
| 2012 | 42.52 Billion KRW | -6.38% |
| 2011 | 45.42 Billion KRW | 13.53% |
| 2010 | 40 Billion KRW | -2.68% |
| 2009 | 41.1 Billion KRW | 11.23% |
| 2008 | 36.96 Billion KRW | 1.04% |
| 2007 | 36.57 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 10.21 Billion KRW | 10.71% |
| 2024 Q2 | 9.12 Billion KRW | -8.8% |
| 2023 Q2 | 10.66 Billion KRW | 5.45% |
| 2023 Q1 | 10.11 Billion KRW | -7.13% |
| 2023 Q4 | 9.22 Billion KRW | -17.26% |
| 2023 FY | 40.64 Billion KRW | -3.34% |
| 2023 Q3 | 11.14 Billion KRW | 4.52% |
| 2022 Q3 | 10.88 Billion KRW | 5.12% |
| 2022 Q4 | 10.88 Billion KRW | -0.01% |
| 2022 FY | 42.05 Billion KRW | 25.38% |
| 2022 Q1 | 9.91 Billion KRW | 37.5% |
| 2022 Q2 | 10.35 Billion KRW | 4.45% |
| 2021 Q3 | 8.4 Billion KRW | -11.14% |
| 2021 Q4 | 7.21 Billion KRW | -14.21% |
| 2021 Q1 | 8.45 Billion KRW | 21.8% |
| 2021 Q2 | 9.46 Billion KRW | 11.87% |
| 2021 FY | 33.54 Billion KRW | -1.77% |
| 2020 Q1 | 8.93 Billion KRW | 53.26% |
| 2020 FY | 34.14 Billion KRW | 3.24% |
| 2020 Q2 | 10.29 Billion KRW | 15.31% |
| 2020 Q3 | 7.97 Billion KRW | -22.54% |
| 2020 Q4 | 6.94 Billion KRW | -12.93% |
| 2019 Q3 | 8.8 Billion KRW | -4.28% |
| 2019 Q2 | 9.19 Billion KRW | -0.57% |
| 2019 Q1 | 9.24 Billion KRW | 9.75% |
| 2019 FY | 33.07 Billion KRW | -6.02% |
| 2019 Q4 | 5.82 Billion KRW | -33.81% |
| 2018 FY | 35.19 Billion KRW | -2.52% |
| 2018 Q2 | 8.9 Billion KRW | 2.12% |
| 2018 Q4 | 8.42 Billion KRW | -7.8% |
| 2018 Q1 | 8.72 Billion KRW | 4.13% |
| 2018 Q3 | 9.14 Billion KRW | 2.63% |
| 2017 FY | 36.1 Billion KRW | -2.67% |
| 2017 Q2 | 9.34 Billion KRW | 7.04% |
| 2017 Q1 | 8.72 Billion KRW | -6.34% |
| 2017 Q4 | 8.37 Billion KRW | -13.31% |
| 2017 Q3 | 9.66 Billion KRW | 3.42% |
| 2016 Q3 | 8.77 Billion KRW | -4.58% |
| 2016 FY | 37.09 Billion KRW | 1.69% |
| 2016 Q4 | 9.31 Billion KRW | 6.17% |
| 2016 Q1 | 9.8 Billion KRW | 6.1% |
| 2016 Q2 | 9.19 Billion KRW | -6.21% |
| 2015 FY | 36.47 Billion KRW | 3.44% |
| 2015 Q4 | 9.24 Billion KRW | 4.49% |
| 2015 Q3 | 8.84 Billion KRW | -6.89% |
| 2015 Q2 | 9.49 Billion KRW | 6.84% |
| 2015 Q1 | 8.89 Billion KRW | 12.68% |
| 2014 FY | 35.26 Billion KRW | -9.5% |
| 2014 Q2 | 9.24 Billion KRW | 0.62% |
| 2014 Q4 | 7.89 Billion KRW | -11.77% |
| 2014 Q3 | 8.94 Billion KRW | -3.24% |
| 2014 Q1 | 9.18 Billion KRW | 0.53% |
| 2013 Q1 | 11.17 Billion KRW | 19.08% |
| 2013 Q2 | 9.37 Billion KRW | -16.16% |
| 2013 Q3 | 9.27 Billion KRW | -1.03% |
| 2013 FY | 38.96 Billion KRW | -8.37% |
| 2013 Q4 | 9.13 Billion KRW | -1.48% |
| 2012 Q4 | 9.38 Billion KRW | -13.58% |
| 2012 Q3 | 10.86 Billion KRW | -2.46% |
| 2012 Q2 | 11.13 Billion KRW | -0.0% |
| 2012 Q1 | 11.13 Billion KRW | 0.0% |
| 2012 FY | 42.52 Billion KRW | -6.38% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 45.42 Billion KRW | 13.53% |
| 2011 Q3 | 11.01 Billion KRW | -9.88% |
| 2011 Q2 | 12.21 Billion KRW | 1.35% |
| 2011 Q1 | 12.05 Billion KRW | 30.48% |
| 2010 Q3 | 10.68 Billion KRW | 1.66% |
| 2010 FY | 40 Billion KRW | -2.68% |
| 2010 Q4 | 9.23 Billion KRW | -13.56% |
| 2010 Q1 | 9.56 Billion KRW | 0.27% |
| 2010 Q2 | 10.51 Billion KRW | 9.94% |
| 2009 Q3 | 10.57 Billion KRW | -1.8% |
| 2009 Q1 | 10.23 Billion KRW | 39.53% |
| 2009 FY | 41.1 Billion KRW | 11.23% |
| 2009 Q2 | 10.76 Billion KRW | 5.21% |
| 2009 Q4 | 9.53 Billion KRW | -9.78% |
| 2008 Q2 | 12.04 Billion KRW | 15.7% |
| 2008 Q1 | 10.4 Billion KRW | 41.31% |
| 2008 FY | 36.96 Billion KRW | 1.04% |
| 2008 Q4 | 7.33 Billion KRW | 2.24% |
| 2008 Q3 | 7.17 Billion KRW | -40.44% |
| 2007 Q1 | 9.35 Billion KRW | 0.0% |
| 2007 Q4 | 7.36 Billion KRW | -22.8% |
| 2007 FY | 36.57 Billion KRW | 0.0% |
| 2007 Q2 | 10.31 Billion KRW | 10.18% |
| 2007 Q3 | 9.54 Billion KRW | -7.46% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 12.591% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 88.836% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 79.561% |
| HANDOK Inc. | 151.36 Billion KRW | 73.145% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 39.532% |
| Yuhan Corporation | 564.5 Billion KRW | 92.799% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 87.384% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -71.177% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 95.137% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 45.829% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 79.569% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 56.992% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 71.141% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 12.591% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -17.093% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 47.083% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 437.464% |
| JW Holdings Corporation | 446.15 Billion KRW | 90.889% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 80.413% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 93.797% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 87.89% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 48.296% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 45.972% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 43.708% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 77.886% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 12.591% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 86.226% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 94.036% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 87.89% |
| Yuhan Corporation | 564.5 Billion KRW | 92.799% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 79.859% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 42.698% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 58.951% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 87.89% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 72.137% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 76.569% |
| CKD Bio Corp. | 5.01 Billion KRW | -711.32% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 84.011% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 77.923% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 58.574% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 48.296% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 89.058% |
| Boryung Corporation | 333.26 Billion KRW | 87.803% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 18.775% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 79.569% |
| JW Lifescience Corporation | 51.32 Billion KRW | 20.8% |